

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 January 2023 (26.01.2023)



(10) International Publication Number
WO 2023/004257 A1

(51) International Patent Classification:

C07D 498/04 (2006.01) *A61P 17/00* (2006.01)
A61P 1/00 (2006.01) *A61P 25/00* (2006.01)
A61P 1/16 (2006.01) *A61P 29/00* (2006.01)
A61P 5/00 (2006.01) *A61P 35/00* (2006.01)
A61P 9/00 (2006.01) *A61P 37/00* (2006.01)
A61P 11/00 (2006.01) *A61K 31/4188* (2006.01)

(21) International Application Number:

PCT/US2022/073756

(22) International Filing Date:

15 July 2022 (15.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/107085
19 July 2021 (19.07.2021) CN
PCT/CN2022/077518
23 February 2022 (23.02.2022) CN

(71) Applicant: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US).

(72) Inventors: **LAI, Kwong Wah**; c/o WuXi AppTec (Shanghai) Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). **NILEWSKI, Christian**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). **PASTOR, Richard M.**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). **STIVALA, Craig**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US).

(74) Agent: **MACKENZIE, Katherine J.** et al.; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

(54) Title: SULFONIMIDAMDE COMPOUNDS AND USES THEREOF




FIG. 1

(57) Abstract: Described herein are sulfonimidamide compounds, solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing. Further described herein are methods of treating a disorder in a subject in need thereof using said compounds, solvates, tautomers, or pharmaceutically acceptable salts thereof, such as NLRP3-mediated disorders.

[Continued on next page]

LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*